Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yale University
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
willingness to participate in a naturalistic treatment study using paliperidone and in two fear conditioning tests, one at baseline and one at the end of the 6 weeks treatment study.
We will include PTSD subjects on medications (possible medications include antidepressants, benzodiazepines) who have no or only partial treatment response. Paliperidone will be added to the existing treatment regime which will remain unchanged during the study period. PTSD subjects will have a minimum score of 50 on the Clinician-Administered PTSD Scale (CAPS; Blake et al, 1995).
You may not be if
a comorbid diagnosis of bipolar illness, schizophrenia or other psychotic disorders, acute or chronic suicidality, acute or chronic unstable medical conditions (including severely impaired hepatic function as indicated with abnormal PT and PTT, abnormal CBC, and liver enzymes more than 50% above the upper normal range, not well controlled blood pressure)
current diagnosis of substance abuse or dependence
unsuccessful treatment history with paliperidone
known hypersensitivity to paliperidone or any of its inactive ingredients
administration of any investigational drug up to 90 days before entry into the study
intake of Class 1A (e.g., quinidine, procainamid) or Class III (e.g., amiodaronme, sotalol) antiarrhythmic medications, antipsychotics, antibiotics (e.g., gatifloxacin, moxifloxacin) (up to 90 days before entry into the study or during the study)
subjects with a positive screen for drugs of abuse
no startle or skin conductance response, or excessively high startle response to the startle probe (100 dB acoustic stimuli) during the pretest.
Clareo Health | Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)
